Karyopharm Therapeutics (KPTI) Total Liabilities (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Total Liabilities came in at $401.3 million in Q4 2025, up 14.53% YoY from $350.4 million in Q4 2024, and up 9.81% on a QoQ basis from $365.5 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Total Liabilities (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Total Liabilities data on file, last reported at $401.3 million in Q4 2025.
- Quarterly Total Liabilities rose 14.53% year-over-year to $401.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $401.3 million (up 14.53% YoY) and the FY2025 annual result came in at $401.3 million, up 14.53% from the prior year.
- Total Liabilities climbed to $401.3 million in Q4 2025, from $365.5 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $401.3 million in Q4 2025 to a low of $314.5 million in Q1 2021.
- A 5-year average of $364.8 million and a median of $370.7 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2021 — Total Liabilities soared 49.74% — and 2025, when it fell 10.66%.
- Tracing KPTI's Total Liabilities over 5 years: stood at $385.0 million in 2021, then slipped by 2.64% to $374.8 million in 2022, then climbed by 0.48% to $376.6 million in 2023, then declined by 6.96% to $350.4 million in 2024, then increased by 14.53% to $401.3 million in 2025.
- The last three Total Liabilities figures came in at $401.3 million (Q4 2025), $365.5 million (Q3 2025), and $343.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 10.03 Bn |
| 10 | Karyopharm Therapeutics | 55.83 Mn | 55.83 Mn | 32.35 Mn | 441.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 441.49 Mn |
| Dec 31, 2025 | 401.34 Mn |
| Sep 30, 2025 | 365.49 Mn |
| Jun 30, 2025 | 343.81 Mn |
| Mar 31, 2025 | 333.60 Mn |
| Dec 31, 2024 | 350.44 Mn |
| Sep 30, 2024 | 349.12 Mn |
| Jun 30, 2024 | 346.12 Mn |
| Mar 31, 2024 | 373.41 Mn |
| Dec 31, 2023 | 376.64 Mn |
| Sep 30, 2023 | 370.36 Mn |
| Jun 30, 2023 | 369.08 Mn |
| Mar 31, 2023 | 370.97 Mn |
| Dec 31, 2022 | 374.83 Mn |
| Sep 30, 2022 | 371.52 Mn |
| Jun 30, 2022 | 372.82 Mn |
| Mar 31, 2022 | 377.11 Mn |
| Dec 31, 2021 | 384.98 Mn |
| Sep 30, 2021 | 380.07 Mn |
| Jun 30, 2021 | 369.70 Mn |